<DOC>
	<DOCNO>NCT02838238</DOCNO>
	<brief_summary>Our study prospective , randomized phase II clinical trial , compare efficacy safety profile single X versus placebo adjuvant chemotherapy regimen elder breast cancer patient .</brief_summary>
	<brief_title>X Versus Placebo Postoperative Adjuvant Treatment Elder Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Age &gt; = 70 year old . Performance status ( Karnofsky index ) &gt; = 80 . Histological diagnosis invasive breast cancer ( T3T4 , N01 , M0 ) . Tumor must bu hormone receptor negative . Time window surgery study randomization must less 60 day . Positive axillary lymph node define least 1 10 node presence disease . If sentinel node technique use , sentinel node node affect . Status hormone receptor , HER2 status , Ki67 index p53 primary tumour . ER PR negative . And patient positive HER2 status revceive standard antitargeted therapy . Written informed consent . Patients able comply treatment study followup . Patients must present evidence metastatic disease . Normal electrocardiogram ( EKG ) 12 week prior randomization . If need , normal cardiac function must confirm leave ventricular ejection fraction ( LVEF ) . Laboratory result ( within 14 day prior randomization ) : Hematology : neutrophil &gt; = 2.0x10^9/l ; platelet &gt; = 100x10^9/l ; hemoglobin &gt; = 10 mg/dl ; Hepatic function : total bilirubin &lt; = 1 upper normal limit ( UNL ) ; SGOT SGPT &lt; = 2.5 UNL ; alkaline phosphatase &lt; = 2.5 UNL . If value SGOT SGPT &gt; 1.5 UNL associate alkaline phosphatase &gt; 2.5 UNL , patient eligible ; Renal function : creatinine &lt; = 175 mmol/l ( 2 mg/dl ) ; creatinine clearance &gt; = 60 ml/min . Â·Complete stage workup 12 week prior randomization ( mammogram allow within 20 week window ) . All patient must bilateral mammogram , thorax xray , abdominal echography and/or compute tomography ( CT ) scan . If bone pain , and/or alkaline phosphatase elevation , bone scintigraphy mandatory . This test recommend patient . Other test : clinically indicate . Prior systemic therapy breast cancer.Or prior therapy capecitabine malignancy . Prior radiotherapy breast cancer . Bilateral invasive breast cancer . Any T4 N23 M1 tumour . Preexisting grade &gt; = 2 motor sensorial neurotoxicity ( National Cancer Institute Common Toxicity Criteria version 2.0 [ NCI CTC v2.0 ] ) . Any serious medical pathology , congestive heart failure ; unstable angina ; history myocardial infarction previous year ; uncontrolled HA high risk arrhythmias . History neurological psychiatric disorder , could preclude patient free informed consent . Active uncontrolled infection . Active peptic ulcer ; unstable diabetes mellitus . Previous current history neoplasms different breast cancer , except skin carcinoma , cervical situ carcinoma , tumour curatively treat without recurrence last 10 year ; ductal situ carcinoma breast ; lobular situ carcinoma . Chronic treatment corticosteroid . Concomitant treatment raloxifene , tamoxifen selective estrogen receptor modulators ( SERMs ) , either osteoporosis treatment prevention . These treatment must stop randomisation . Concomitant treatment investigational product ; participation clinical trial nonmarketed drug 20 previous day randomization . Concomitant treatment another therapy cancer . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>